Kun-Long Hung | Personalized Medicine | Top Pharmaceutical Breakthrough Discovery Award

Published on by Top Pharmaceutical

Top Pharmaceutical Breakthrough Discovery Award

Kun-Long Hung
Fu Jen Catholic University Hospital, Taiwan

Kun-Long Hung
Affiliation Fu Jen Catholic University Hospital
Country Taiwan
Scopus ID 7202728402
Documents 81
Citations 1,862
h-index 23
Subject Area Personalized Medicine
Event International Top Pharmaceutical Awards

Kun-Long Hung is a Taiwanese clinician and researcher associated with Fu Jen Catholic University Hospital. His scholarly record demonstrates sustained contributions to personalized medicine, pediatric neurology, genetic disorders, developmental diseases, and translational healthcare research. According to Scopus metrics, his publication portfolio includes more than eighty indexed documents and a substantial citation impact within the medical research community.[1]

Abstract

This article summarizes the academic profile and scientific achievements of Kun-Long Hung. His research activities have focused on personalized medicine approaches, pediatric neurological disorders, genetic diagnostics, and evidence-based clinical practice. Through multidisciplinary collaborations, he has contributed to improved understanding of rare diseases and patient-centered healthcare strategies.[1]

Keywords

Personalized Medicine, Pediatric Neurology, Genetic Disorders, Clinical Research, Rare Diseases, Translational Medicine, Precision Healthcare, Developmental Disorders, Neurogenetics, Medical Innovation.

Introduction

The advancement of personalized medicine depends on researchers who integrate clinical observations with scientific investigation. Kun-Long Hung has participated in studies addressing neurological and genetic conditions affecting children and families. His published work reflects an ongoing commitment to improving diagnostic accuracy and therapeutic decision-making in modern healthcare environments.[2]

Research Profile

Based in Taiwan, Hung has established a recognized publication record supported by 81 indexed documents, 1,862 citations, and an h-index of 23. His research portfolio spans neurodevelopmental disorders, pediatric epilepsy, genetic syndromes, and precision medicine applications. These metrics indicate consistent scholarly engagement and meaningful influence across multiple areas of clinical medicine.[1]

Research Contributions

Hung has contributed to investigations involving developmental delay, neurofibromatosis, Dravet syndrome, tubulinopathy, and other neurological disorders. His work frequently combines genetic evaluation with clinical assessment to support individualized treatment planning. Such contributions align closely with contemporary precision medicine objectives and patient-focused healthcare models.[3]

Publications

Among his notable publications are studies on neurofibromatosis management in Taiwan, neurological manifestations of SARS-CoV-2 infection in children, developmental delay diagnostics, and rare genetic disorders. These publications demonstrate continued participation in clinically relevant research that addresses both local and international healthcare challenges while supporting evidence-based practice.[2]

Research Impact

The citation performance associated with Hung’s publications reflects engagement from researchers across medical and scientific disciplines. His studies have contributed to discussions involving diagnosis, disease management, and long-term outcomes in pediatric populations. This influence supports continued visibility within international biomedical literature and healthcare research communities.[1]

Award Suitability

The International Top Pharmaceutical Awards recognize researchers whose work advances healthcare innovation and scientific understanding. Hung’s contributions to personalized medicine, combined with his publication record and citation impact, align with the objectives of recognizing meaningful research achievements. His work illustrates the integration of clinical expertise and translational investigation.[4]

Conclusion

Kun-Long Hung has developed a substantial academic profile through research focused on pediatric neurology, genetic medicine, and individualized healthcare. His scientific contributions, publication metrics, and collaborative activities demonstrate continued involvement in advancing medical knowledge. These achievements provide a strong foundation for recognition within international research and healthcare award programs.

References

  1. Elsevier. (n.d.). Scopus Author Profile: Hung, K. L. (Author ID: 7202728402). Scopus. https://www.scopus.com/authid/detail.uri?authorId=7202728402
  2. Chu, Y. J., Wong, L. C., Ho, C. S., Lee, W. T., & Hung, K. L. (2024). Neurological manifestations of SARS-CoV-2 infection in children in Taiwan: A cross-sectional multicenter study. Journal of the Formosan Medical Association. https://doi.org/10.1016/j.jfma.2024.01.001
  3. Huang, C. S., Hung, P. L., Fan, P. C., Lee, W. T., & Hung, K. L. (2021). Clinical spectrum and comorbidities of Dravet syndrome in Taiwan and possible molecular mechanisms. Scientific Reports, 11, Article 15092. https://pubmed.ncbi.nlm.nih.gov/34642351/
  4. Hung, K. L., Lu, J. F., Su, D., Hsu, S., & Wong, L. C. (2022). Tubulinopathy presenting as developmental and epileptic encephalopathy. Children, 9(11), 1663. https://doi.org/10.3390/children9111663
  5. Liang, J. S., Hung, K. L., Lin, L., Keng, W. T., & Lu, J. F. (2023). Novel PEX1 mutations in fibroblasts from children with Zellweger spectrum disorders exhibit temperature-sensitive characteristics. Epilepsy & Behavior, 147, 109387. https://doi.org/10.1016/j.yebeh.2023.109387

juan iovanna | Personalized Medicine | Best Researcher Award

Published on by Top Pharmaceutical

juan iovanna | Personalized Medicine | Best Researcher Award

Prof. Dr. juan iovanna, INSERM, France

Prof. Dr. Juan Iovanna è un medico e ricercatore internazionale esperto in oncologia, specializzato nello studio del carcinoma pancreatico. Laureato e dottorato all’Università di Buenos Aires, lavora in Francia dal 1991 presso l’INSERM, dove ha raggiunto il grado di Direttore di Ricerca di Classe Eccezionale. Co-dirige il gruppo “Biologia del cancro pancreatico” al CRCM di Marsiglia e presiede il Programma G7 Cancer. Fondatore di tre start-up biotecnologiche, ha pubblicato 472 articoli con oltre 43.500 citazioni 📚. La sua missione è migliorare la prognosi del tumore pancreatico attraverso ricerca e innovazione terapeutica.

Publication Profile

orcid

Education

Prof. Dr. Juan Iovanna began his academic journey with a degree in Medicine from the University of Buenos Aires, Argentina, in 1982. Driven by a passion for biomedical research, he pursued a Ph.D. in Biomedical Sciences at the same university, which he completed in 1986. 🧬 His doctoral thesis, titled “Meccanismi di regolazione della sintesi proteica in modelli cellulari di stress,” focused on the mechanisms regulating protein synthesis in cellular stress models. 🧪 This foundational work laid the groundwork for his future contributions to medical science and molecular biology.

Experience

🔬 Prof. Dr. Juan Iovanna has built an illustrious career in cancer research. In 1991, he began as a researcher at INSERM in France and was promoted to Research Director in 1993 and again in 1998. 🚀 In 2011, he achieved the prestigious title of Directeur de Recherche de Classe Exceptionnelle (DRCE). From 2011 to 2023, he served as Vice-Director of the Marseille Cancer Research Center (CRCM) and led its Translational Medicine Department. 🧫 He also directed the “Pancreatic Cancer Biology” group from 1999 to 2023. Since 2024, he co-directs this group with Dr. Nelson Dusetti and serves as Emeritus Research Director.

Distinctions and Awards

Prof. Dr. Juan Iovanna has received numerous prestigious awards and honors throughout his career. In 2017, he was awarded the Jean Valade Prize by the Fondation de France for his outstanding contributions to biomedical research. 🌍 In 2018, he received the RAICES Award from Argentina’s Ministry of Science, Technology, and Innovation. 🇫🇷 In 2021, the French Senate honored him with a commemorative medal. In 2023, he was named Honorary Professor at the National University Arturo Jauretche (UNAJ), and in 2024, he was recognized as a Distinguished and Honorary Member of the University of Buenos Aires.

Research Focus

Prof. Dr. Juan Iovanna’s research is centered on precision oncology, with a primary focus on pancreatic ductal adenocarcinoma (PDAC). His work integrates transcriptomics, drug resistance mechanisms, redox metabolism, and multi-omics modeling to uncover novel therapeutic vulnerabilities and biomarkers. He contributes to the development of RNA signatures (like GemPred) to predict chemotherapy response, and investigates KRAS inhibition and therapy-induced senescence as pathways to reverse drug resistance. His translational studies aim to optimize personalized treatment strategies for pancreatic cancer patients, bridging molecular insights with clinical application.

Publication Top Notes

KRAS inhibition reverses chemotherapy resistance promoted by therapy-induced senescence-like in pancreatic ductal adenocarcinoma

The PancreasView gemcitabine transcriptomic signature predicts response to gemcitabine in patients with resected pancreatic ductal adenocarcinoma

Adaptation of redox metabolism in drug-tolerant persister cells is a vulnerability to prevent relapse in pancreatic cancer

Reply to the Letter to the Editor regarding ‘Chi-squared and P-values vs. machine learning feature selection by Y. Takefuji’

Reply to the Letter to the Editor ‘AI-assisted personalized adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma’ by Y. Shimazu

Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CCTG PA6 Clinical Trial
Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity
Limitation and challenges in using pancreatic cancer‐derived organoids as a preclinical tool

Multi-omics data integration and modeling unravels new mechanisms for pancreatic cancer and improves prognostic prediction

Henryk Mazurek | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Henryk Mazurek | Precision Medicine | Best Researcher Award

Prof. Henryk Mazurek, National Tuberculosis and Lung Diseases Institute, Department of Pneumonology and Cystic Fibrosis, Poland

Prof. Henryk Mazurek is a distinguished pulmonologist, allergologist, and pediatrician specializing in pediatric pulmonology and respiratory diseases. He serves as the Head of the Department of Pneumonology and Cystic Fibrosis at the National Tuberculosis and Lung Diseases Institute, Poland 🇵🇱. With over 60 original research articles and extensive contributions to medical literature 📚, he has significantly advanced the understanding of chronic respiratory diseases, asthma, and cystic fibrosis. A member of esteemed scientific societies 🌍, he actively collaborates internationally and leads impactful research projects. His work in AI-assisted diagnostics and pulmonary care is shaping the future of respiratory medicine. 🚀

Publication Profile

Scopus

Professional Background

Professor Henryk Mazurek is a distinguished pulmonary disease specialist, allergologist, pediatrician, and pediatric pulmonology expert 🩺. He completed postgraduate studies in respiratory pathophysiology in France 🇫🇷 and holds the title of Full Professor in medical and health sciences 🎓. As an academic, he teaches nursing and postgraduate medical training in pediatrics, allergology, and lung diseases. He has authored and co-authored over 60 original articles, 100+ textbook chapters, and numerous scientific publications 📚. A sought-after lecturer, he shares his expertise at medical conferences, educating physicians and healthcare professionals worldwide 🌍.

Memberships

Prof. Henryk Mazurek is an esteemed member of several prestigious scientific organizations, fostering international collaboration in respiratory medicine 🌍🫁. He holds a combined membership in the European Respiratory Society (ERS) / Polish Respiratory Society, along with memberships in the Polish Society of Allergology and the Polish Society of Pediatric Pulmonology, where he is an honorary member 🎖️. For many years, he contributed to the Scientific Council of the Institute of Tuberculosis and Lung Diseases in Warsaw 🏥. Additionally, he served on the Main Boards of the Polish Society of Allergology (2015-2021) and the Polish Society of Cystic Fibrosis (2014-2018) 📚.

Industry Projects

Prof. Henryk Mazurek has actively contributed to over 50 industry-sponsored clinical trials, showcasing his expertise in applied research 🔬. His consultancy work plays a crucial role in bridging academic research with real-world healthcare applications, particularly in advancing treatment strategies for cystic fibrosis 🫁. Through his collaborations with pharmaceutical and medical device companies 💊🩺, he has successfully translated research findings into clinical practice, improving patient outcomes. His dedication to innovation and evidence-based solutions continues to shape the future of respiratory medicine, reinforcing his impact on both academia and industry. 🌍

Research Focus

Prof. Henryk Mazurek’s research primarily focuses on respiratory diseases 🫁, particularly in cystic fibrosis 🧬, pediatric pulmonology 👶, and ventilator-associated pneumonia 🏥. His work explores innovative AI-facilitated home monitoring 🤖 for cystic fibrosis, childhood asthma treatments 🌬️, and the effects of medications like Gabapentin on post-operative pain 💊. He has also studied risk factors for pneumonia 🦠 and strategies for its prevention in ventilated patients. His expertise lies in pulmonary infections, inflammatory biomarkers, and personalized medicine 🧑‍⚕️. His contributions significantly impact respiratory healthcare, enhancing diagnostic and therapeutic approaches for both pediatric and adult patients.

Publication Top Notes

AI-facilitated home monitoring for cystic fibrosis exacerbations across pediatric and adult populations

Childhood asthma treatment based on indirect hyperresponsiveness test: Randomized controlled trial

The Effects of Gabapentin on Post-Operative Pain and Anxiety, Morphine Consumption and Patient Satisfaction in Paediatric Patients Following the Ravitch Procedure—A Randomised, Double-Blind, Placebo-Controlled, Phase 4 Trial

Risk Factors and Protective Factors against Ventilator-Associated Pneumonia—A Single-Center Mixed Prospective and Retrospective Cohort Study

Automatic continuous control of cuff pressure and subglottic secretion suction used together to prevent pneumonia in ventilated patients—a retrospective and prospective cohort study

Chronic bacterial pulmonary infections in advanced cystic fibrosis differently affect the level of sputum neutrophil elastase, IL-8 and IL-6